|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4985 | (2006.01) |
| A61K 31/4985 | (2013.01) | ||
| A61P 31/12 | (2006.01) | ||
| A61P 31/12 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/44 | (2013.01) | ||
| A61K 31/44 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| G01N 33/50 | (2006.01) |
| (11) | Number of the document | 3641772 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18819790.9 |
| Date of filing the European patent application | 2018-06-21 | |
| (97) | Date of publication of the European application | 2020-04-29 |
| (45) | Date of publication and mention of the grant of the patent | 2023-08-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2018/038697 |
| Date | 2018-06-21 |
| (87) | Number | WO 2018/237114 |
| Date | 2018-12-27 |
| (30) | Number | Date | Country code |
| 201762523688 P | 2017-06-22 | US |
| (72) |
FILVAROFF, Ellen , US
HEGE, Kristen, M. , US
LI, Shaoyi , US
|
| (73) |
Celgene Corporation ,
86 Morris Avenue, Summit, NJ 07901,
US
|
| (54) | TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION |
| TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION |